SU5416 in Treating Patients With Advanced Solid Tumors

Phase 1 Completed 19 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have advanced solid tumors.

Timeline

Start: 2000-05
Primary completion: 2002-12
Completion: 2005-11

Publications

Results Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002 Sep;8(9):2798-805.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	semaxanib	Small molecule	65 mg/m2	Intravenous
Subject	semaxanib	Small molecule	145 mg/m2	Intravenous
Subject	semaxanib	Small molecule	190 mg/m2	Intravenous

SU5416 in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications